A double-blind, placebo-controlled study of the effect of MK-0966 [rofecoxib] on blood and synovial fluid prostaglandin levels and synovial fluid MK-0966 concentrations in patients with rheumatoid arthritis (RA)

Trial Profile

A double-blind, placebo-controlled study of the effect of MK-0966 [rofecoxib] on blood and synovial fluid prostaglandin levels and synovial fluid MK-0966 concentrations in patients with rheumatoid arthritis (RA)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2006

At a glance

  • Drugs Diclofenac; Rofecoxib
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top